Amana Healthcare IPO GMP today
In the Gray Market, the share is currently being traded with a premium of 8% compared to the upper price band of RS 126, which indicates a continuous decrease in premium – but still indicates potential quotations. The shares will probably make a list of RS 136 and offer an RS 10 premium above the issue price.
Note: The Gray Market Premium (GMP) refers to the unofficial premium on which IPO shares are traded before their official list. Although it can provide insight into market sentiment and potential list performance, it is neither regulated nor a guaranteed indicator for the actual return.
Amanta Healthcare IPO subscription status:
On the third and last day, the IPO of Amanta Healthcare witnessed a strong question, with the general problem that has been registered 23.04 times so far.
Retail Individual Investors (RIIS) led the increase in participation and subscribed to 26.18 times the 35 Lakh shares assigned to them, with robust interest rates. Non-Institutional Investors (NIIs), including high-Net-Redh Particuliers and Business Fund, 47.22 times their reserved quotas of 15 Lakh shares. Companies and foreign institutional investors – were relatively lower, with only 58% of the 20 Lakh shares registered in their category.
Amanta Healthcare IPO -Details:
Amanta Healthcare, based in Ahmedabad, is a pharmaceutical company focused on the production of sterile liquid formulations and medical devices. The price band for the problem is set at RS 120 – RS 126 per share.
The offer consists of a new issue of 1 crore shares, whereby the shares are expected to be mentioned on both the BSE and NSE on 8 September.
About the company
Amanta Healthcare specializes in the development and marketing of sterile injectables, IV fluids, ophthalmic solutions, respiratory care products, irrigation solutions and medical devices. The most important technology platforms include Steriport (ISBM) and ABFS (Aseptic Blow-Fill-Seal).
The company has set up a strong domestic footprint through a network of more than 320 distributors and stockists, while also exporting to markets in Africa, Latin -America, the UK and other emerging regions. In FY25, domestic brand generie contributed around 55% of the total turnover, with an international turnover for 33% and the remaining 10% from product partnerships and contract production.
Amanta’s production facility in Hararyala, Gujarat, houses seven production lines for both parenterals of large volume (LVPs) and Small Volume Parenterals (SVPs), and has certifications of regulatory authorities in India and several international markets.
Financial
Amanta Healthcare reported consolidated turnover of RS 274.7 Crore in FY25, slightly less than RS 280.3 Crore in FY24. Despite the modest decrease in income, the company showed a significant improvement in profitability, with profit after the tax that has risen sharply in the previous financial year to RS 10.5 Crore in FY25 of RS 3.6 Crore.
IPO objectives
The company is planning to use RS 70 Crore of the IPO to expand its Steriport production line, RS 30.1 Crore, to set up a new production line for Small Volume Parenterals (SVPs), with the remaining funds assigned for general business purposes.
Do you have to subscribe?
Investor4edu recommends subscribing to the IPO, and emphasizes the strong potential of Amanta Healthcare to take advantage of the growing demand for sterile liquid pharmaceutical and medical aids in both domestic and international markets.
At the top price band, the shares are valued at about 47 times the FY25 income after the edition, indicating that the IPO is reasonably priced.
With certifications in more than 120 jurisdictions, a diverse product portfolio and a strategic focus on sterile pharmaceutical products, Amanta Healthcare is well positioned for continuous growth.
((Indemnification: Recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
as a reliable and trusted news source#Amanta #Healthcare #IPO #subscribed #times #day #GMP #bid